Header Logo

Connection

C OSBORNE to Aged

Back to Details
This is a "connection" page, showing publications C OSBORNE has written about Aged.
C OSBORNE
Connection Strength
0.241
Aged
  1. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59.
    View in: PubMed
    Score: 0.016
  2. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20; 23(33):8313-21.
    View in: PubMed
    Score: 0.011
  3. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
    View in: PubMed
    Score: 0.011
  4. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 01; 22(9):1605-13.
    View in: PubMed
    Score: 0.010
  5. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
    View in: PubMed
    Score: 0.009
  6. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26; 339(22):1609-18.
    View in: PubMed
    Score: 0.007
  7. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res. 1998 May; 4(5):1263-6.
    View in: PubMed
    Score: 0.007
  8. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998 Jan; 4(1):7-12.
    View in: PubMed
    Score: 0.007
  9. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul; 15(7):2494-501.
    View in: PubMed
    Score: 0.006
  10. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997 May; 44(1):65-74.
    View in: PubMed
    Score: 0.006
  11. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct; 12(10):2078-85.
    View in: PubMed
    Score: 0.005
  12. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Ann Oncol. 1994 Jan; 5(1):43-7.
    View in: PubMed
    Score: 0.005
  13. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993 Sep; 11(9):1710-6.
    View in: PubMed
    Score: 0.005
  14. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol. 1992 Feb; 10(2):304-10.
    View in: PubMed
    Score: 0.004
  15. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat. 1992; 22(3):273-84.
    View in: PubMed
    Score: 0.004
  16. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer. 1992; 28(2-3):477-8.
    View in: PubMed
    Score: 0.004
  17. A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer. 1991 Oct 15; 68(8):1694-5.
    View in: PubMed
    Score: 0.004
  18. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 07; 83(15):1077-84.
    View in: PubMed
    Score: 0.004
  19. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1991 Feb; 9(1):87-8.
    View in: PubMed
    Score: 0.004
  20. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010 Dec 15; 16(24):6169-76.
    View in: PubMed
    Score: 0.004
  21. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15.
    View in: PubMed
    Score: 0.004
  22. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol. 1990 Oct; 8(10):1675-82.
    View in: PubMed
    Score: 0.004
  23. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9.
    View in: PubMed
    Score: 0.004
  24. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063.
    View in: PubMed
    Score: 0.004
  25. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
    View in: PubMed
    Score: 0.004
  26. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9.
    View in: PubMed
    Score: 0.004
  27. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66.
    View in: PubMed
    Score: 0.004
  28. Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer. Invest New Drugs. 1989 Jul; 7(2-3):243-5.
    View in: PubMed
    Score: 0.004
  29. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009 May 01; 27(13):2157-62.
    View in: PubMed
    Score: 0.004
  30. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20; 25(6):656-61.
    View in: PubMed
    Score: 0.003
  31. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.003
  32. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
    View in: PubMed
    Score: 0.003
  33. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
    View in: PubMed
    Score: 0.003
  34. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol. 2006 Feb; 20(2):311-20.
    View in: PubMed
    Score: 0.003
  35. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61.
    View in: PubMed
    Score: 0.003
  36. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76.
    View in: PubMed
    Score: 0.003
  37. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
    View in: PubMed
    Score: 0.003
  38. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005 Jan 01; 23(1):24-9.
    View in: PubMed
    Score: 0.003
  39. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
    View in: PubMed
    Score: 0.003
  40. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004 Sep 01; 10(17):5670-6.
    View in: PubMed
    Score: 0.003
  41. Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep. 1984 Feb; 68(2):357-60.
    View in: PubMed
    Score: 0.002
  42. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep. 1983 Dec; 67(12):1133-5.
    View in: PubMed
    Score: 0.002
  43. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38.
    View in: PubMed
    Score: 0.002
  44. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003 May 15; 21(10):1973-9.
    View in: PubMed
    Score: 0.002
  45. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003 May; 79(2):207-11.
    View in: PubMed
    Score: 0.002
  46. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
    View in: PubMed
    Score: 0.002
  47. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 01; 97(1):21-9.
    View in: PubMed
    Score: 0.002
  48. Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol. 1982; 8(3):261-5.
    View in: PubMed
    Score: 0.002
  49. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 2000 Feb; 6(2):616-21.
    View in: PubMed
    Score: 0.002
  50. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63.
    View in: PubMed
    Score: 0.002
  51. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May; 17(5):1474-81.
    View in: PubMed
    Score: 0.002
  52. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998 Jul; 16(7):2382-91.
    View in: PubMed
    Score: 0.002
  53. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
    View in: PubMed
    Score: 0.002
  54. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.002
  55. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr; 3(4):593-600.
    View in: PubMed
    Score: 0.002
  56. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996 Nov; 14(11):3009-17.
    View in: PubMed
    Score: 0.002
  57. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.001
  58. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
    View in: PubMed
    Score: 0.001
  59. Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1994; 12(2):129-32.
    View in: PubMed
    Score: 0.001
  60. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6.
    View in: PubMed
    Score: 0.001
  61. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
    View in: PubMed
    Score: 0.001
  62. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan; 5(1):55-61.
    View in: PubMed
    Score: 0.001
  63. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs. 1985; 3(2):149-52.
    View in: PubMed
    Score: 0.001
  64. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct; 2(10):1102-9.
    View in: PubMed
    Score: 0.001
  65. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983 Aug 01; 52(3):393-8.
    View in: PubMed
    Score: 0.001
  66. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983 Jan; 43(1):413-6.
    View in: PubMed
    Score: 0.001
  67. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer. 1976 Aug; 38(2):1026-35.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.